Last reviewed · How we verify
3-Propylxanthine (ENPROFYLLINE)
3-Propylxanthine (generic name: ENPROFYLLINE) is a enprofylline drug. It is currently in Phase 2 development.
Enprofylline works by blocking the adenosine receptor A2b, which helps to increase blood flow and reduce inflammation.
3-Propylxanthine, also known as enprofylline, is a small molecule drug that targets the adenosine receptor A2b. It belongs to the enprofylline drug class and is used to treat various conditions, although its approved indications are currently unknown. The commercial status of enprofylline is also unclear, with information on its patent status and generic availability not readily available. Key safety considerations include its relatively short half-life of 1.8 hours, although further details on its bioavailability and potential side effects are lacking. As a result, more research is needed to fully understand the properties and applications of enprofylline.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ENPROFYLLINE |
|---|---|
| Drug class | enprofylline |
| Target | Adenosine receptor A3, Adenosine receptor A1, Adenosine receptor A2a |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 2 |
Mechanism of action
Think of adenosine like a brake pedal in your car. When adenosine binds to its receptor, it slows down the flow of blood. Enprofylline is like a brake pad remover - it takes the adenosine out of the way, allowing blood to flow more freely and reducing inflammation in the process.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 3-Propylxanthine CI brief — competitive landscape report
- 3-Propylxanthine updates RSS · CI watch RSS
Frequently asked questions about 3-Propylxanthine
What is 3-Propylxanthine?
How does 3-Propylxanthine work?
What is the generic name of 3-Propylxanthine?
What drug class is 3-Propylxanthine in?
What development phase is 3-Propylxanthine in?
What does 3-Propylxanthine target?
Related
- Drug class: All enprofylline drugs
- Target: All drugs targeting Adenosine receptor A3, Adenosine receptor A1, Adenosine receptor A2a
- Therapeutic area: All drugs in Hematology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing